Otsuka Holdings Co., Ltd. (OTSKY)
USD 27.55
(-0.4%)
USD 27.55
(-0.4%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 214.18 Billion JPY | 10.31% |
| 2022 | 194.16 Billion JPY | -8.61% |
| 2021 | 212.45 Billion JPY | -6.03% |
| 2020 | 226.07 Billion JPY | -10.75% |
| 2019 | 253.31 Billion JPY | 23.04% |
| 2018 | 205.88 Billion JPY | -14.72% |
| 2017 | 241.43 Billion JPY | -11.64% |
| 2016 | 273.23 Billion JPY | -14.96% |
| 2015 | 321.31 Billion JPY | 239.04% |
| 2014 | 94.77 Billion JPY | 42.54% |
| 2013 | 66.48 Billion JPY | -10.63% |
| 2012 | 74.39 Billion JPY | -19.48% |
| 2011 | 92.4 Billion JPY | -32.2% |
| 2010 | 136.28 Billion JPY | -2.26% |
| 2009 | 139.44 Billion JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 199.46 Billion JPY | -6.87% |
| 2024 Q2 | 247.96 Billion JPY | 24.31% |
| 2023 Q3 | 184.9 Billion JPY | -1.48% |
| 2023 FY | 214.18 Billion JPY | 10.31% |
| 2023 Q4 | 214.18 Billion JPY | 15.84% |
| 2023 Q1 | 190.58 Billion JPY | -1.84% |
| 2023 Q2 | 187.68 Billion JPY | -1.52% |
| 2022 Q3 | 205.55 Billion JPY | -1.66% |
| 2022 Q4 | 194.16 Billion JPY | -5.54% |
| 2022 Q2 | 209.03 Billion JPY | -1.34% |
| 2022 FY | 194.16 Billion JPY | -8.61% |
| 2022 Q1 | 211.87 Billion JPY | -0.27% |
| 2021 Q2 | 216.81 Billion JPY | -4.87% |
| 2021 Q3 | 219.55 Billion JPY | 1.26% |
| 2021 Q4 | 212.45 Billion JPY | -3.23% |
| 2021 FY | 212.45 Billion JPY | -6.03% |
| 2021 Q1 | 227.91 Billion JPY | 0.81% |
| 2020 Q2 | 234.82 Billion JPY | -4.67% |
| 2020 FY | 226.07 Billion JPY | -10.75% |
| 2020 Q3 | 236.16 Billion JPY | 0.57% |
| 2020 Q4 | 226.07 Billion JPY | -4.27% |
| 2020 Q1 | 246.33 Billion JPY | -2.76% |
| 2019 FY | 253.31 Billion JPY | 23.04% |
| 2019 Q1 | 351.44 Billion JPY | 70.7% |
| 2019 Q4 | 253.31 Billion JPY | -22.67% |
| 2019 Q3 | 327.58 Billion JPY | -1.35% |
| 2019 Q2 | 332.05 Billion JPY | -5.52% |
| 2018 FY | 205.88 Billion JPY | -14.72% |
| 2018 Q4 | 205.88 Billion JPY | -22.85% |
| 2018 Q3 | 266.86 Billion JPY | 13.32% |
| 2018 Q2 | 235.5 Billion JPY | -1.43% |
| 2018 Q1 | 238.92 Billion JPY | -1.04% |
| 2017 Q1 | 267.51 Billion JPY | -2.09% |
| 2017 FY | 241.43 Billion JPY | -11.64% |
| 2017 Q4 | 241.43 Billion JPY | -4.58% |
| 2017 Q3 | 253.02 Billion JPY | 0.23% |
| 2017 Q2 | 252.43 Billion JPY | -5.64% |
| 2016 FY | 273.23 Billion JPY | -14.96% |
| 2016 Q4 | 273.23 Billion JPY | -1.88% |
| 2016 Q3 | 278.47 Billion JPY | -1.84% |
| 2016 Q2 | 283.69 Billion JPY | -8.11% |
| 2016 Q1 | 308.72 Billion JPY | -3.92% |
| 2015 Q2 | 327.59 Billion JPY | -2.94% |
| 2015 Q3 | 323.93 Billion JPY | -1.12% |
| 2015 Q4 | 321.31 Billion JPY | -0.81% |
| 2015 Q1 | 337.52 Billion JPY | 0.0% |
| 2015 FY | 321.31 Billion JPY | 239.04% |
| 2014 Q3 | 98.13 Billion JPY | 8.32% |
| 2014 FY | 94.77 Billion JPY | 42.54% |
| 2014 Q2 | 90.59 Billion JPY | 19.78% |
| 2014 Q1 | 75.63 Billion JPY | 57.97% |
| 2013 Q3 | 57.43 Billion JPY | -6.34% |
| 2013 Q4 | 47.88 Billion JPY | -16.64% |
| 2013 Q1 | 66.48 Billion JPY | 28.76% |
| 2013 FY | 66.48 Billion JPY | -10.63% |
| 2013 Q2 | 61.32 Billion JPY | -7.76% |
| 2012 FY | 74.39 Billion JPY | -19.48% |
| 2012 Q4 | 51.63 Billion JPY | -5.61% |
| 2012 Q3 | 54.71 Billion JPY | -22.0% |
| 2012 Q2 | 70.14 Billion JPY | -5.72% |
| 2012 Q1 | 74.39 Billion JPY | -12.98% |
| 2011 Q2 | 88.8 Billion JPY | -3.89% |
| 2011 Q1 | 92.4 Billion JPY | 3.24% |
| 2011 Q3 | 87.57 Billion JPY | -1.38% |
| 2011 Q4 | 85.49 Billion JPY | -2.38% |
| 2011 FY | 92.4 Billion JPY | -32.2% |
| 2010 Q4 | 89.5 Billion JPY | -1.09% |
| 2010 Q3 | 90.48 Billion JPY | -15.67% |
| 2010 Q1 | 136.28 Billion JPY | -0.41% |
| 2010 FY | 136.28 Billion JPY | -2.26% |
| 2010 Q2 | 107.3 Billion JPY | -21.27% |
| 2009 Q3 | 138.91 Billion JPY | -3.41% |
| 2009 FY | 139.44 Billion JPY | 0.0% |
| 2009 Q4 | 136.85 Billion JPY | -1.48% |
| 2009 Q2 | 143.81 Billion JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AstraZeneca PLC | 28.58 Billion USD | -649.388% |
| Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | -416.561% |
| CSPC Pharmaceutical Group Limited | 99.64 Million USD | -214847.97% |
| Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | -506623.604% |
| Novartis AG | 26.34 Billion USD | -712.916% |
| PT Kalbe Farma Tbk. | 40.4 Million USD | -529990.212% |